Table 1.

Clinical Inputs for the Model to Evaluate Rate Complications With Different Surfactant Scenarios

Key Clinical Inputs	Gestational Age, wk	LISA, %	INSURE, %	NIV Success, %	NIV Failure, %
Bronchopulmonary dysplasia	25–28	13.40	16.80	14.20	40.30
	29–32	1.70	2.20	2.60	3.00
Severe intraventricular hemorrhage	25–28	2.70	4.30	6.00	6.00
	29–32
Pneumothorax	25–28	2.40	2.80	5.70	20.20
	29–32	2.90	3.50	0.60	46.20
Retinopathy of prematurity	25–28	4.23	5.16	1.36	1.36
	29–32
Mortality	25–28	1.90	2.80	0.00	13.40
	29–32	0.30	0.40	0.00	0.00
MV requirement	25–28	22.80	31.90	0.00	100
	29–32
Average number of doses per patient	25–28	1.48	1.48	0.00	1.64
	29–32

INSURE, intubation-surfactant-extubation; LISA, less invasive surfactant administration; MV, mechanical ventilation; NIV, non-invasive ventilation

Note: Some cells are splited into two rows, but only one value was given since it applies to both rows.